AGC Biologics Expands Manufacturing Deal With Global Drugmaker to Over €500 Million

• AGC Biologics on Nov. 3, 2026, expanded a long-term manufacturing agreement with an unnamed global pharmaceutical company.
• The expansion brings the deal’s total value above €500 million, adding six commercial biologics programs at its Copenhagen facility.
• The existing agreement covers five commercial biologics programs at its Yokohama facility.
• Dual regulatory submissions will support production transfers between sites to optimize capacity, costs and regional supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030300OMX_____CNEWS_EN_GNW9868669_en) on November 03, 2026, and is solely responsible for the information contained therein.